Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the …
Jun 22, 2023 · Sarepta is responsible for global development and manufacturing for ELEVIDYS, and distribution within the U.S. will commence immediately. In December 2019, Sarepta partnered with Roche to accelerate access to ELEVIDYS for patients outside the United States.
Roche dives deeper into gene therapy with $1.15 billion Sarepta ...
Dec 24, 2019 · Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne...
Roche to pay Sarepta $1B upfront for DMD gene therapy rights
Dec 23, 2019 · Roche is paying more than $1 billion upfront for the ex-U.S. rights to Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy SRP-9001. The deal comes days after Roche advanced...
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for ...
Jul 6, 2022 · Sarepta and its partner Roche present new results and analyses at the International Congress on Neuromuscular Diseases (ICNMD), which demonstrate that SRP-9001 shows consistent, statistically significant functional benefits in individuals with Duchenne versus a propensity-weighted external control
Roche enters licensing agreement with Sarepta Therapeutics to …
Dec 23, 2019 · Under the terms of the agreement, Sarepta will receive an upfront payment of $750million in cash and $400million in equity. In addition, Sarepta is eligible to receive regulatory and sales milestones, and royalties on net sales. Roche and Sarepta will equally share global development expenses.
Roche | Duchenne muscular dystrophy
Together with Sarepta Therapeutics, we are partnering with the Duchenne muscular dystrophy (DMD) community to change the way Duchenne is treated. Duchenne is a rare, genetic, muscle-wasting disease that worsens over time and has no cure.
FDA broadens label for Sarepta's Duchenne gene therapy Elevidys
Jun 21, 2024 · There’s no slowing the momentum of Sarepta’s groundbreaking Duchenne muscular dystrophy (DMD) gene therapy Elevidys—not even the failure of a confirmatory trial. On Thursday, the FDA expanded...
Roche snaps up ex-US rights to Sarepta's DMD gene therapy
Dec 24, 2019 · Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal. The big Swiss pharma will pay $750 million cash up front and...
Update on Sarepta and Roche's SRP-9001 gene therapy
Jun 22, 2023 · A company called Sarepta has developed the therapy, and has a licensing agreement with the drug company Roche to launch SRP-9001 outside the US in places like the UK. You can read more about the history of SRP-9001 and the relationship between Sarepta and Roche in our update from December 2022 here.
Sarepta files Duchenne muscular dystrophy gene therapy with FDA
Mar 4, 2025 · Roche-partnered SRP-9001 (delandistrogene moxeparvovec) has been submitted for approval to treat ambulatory (walking) patients with DMD, a genetic disorder characterised by progressive...